BR1400-1

BR1400-1 is a small molecule drug under development by Boryung Pharmaceutical (also referred to as Boryung Corp.) for the treatment of essential hypertension. It is one of several formulations or dose variants in the BR1400 series (including BR1400-2 and BR1400-3) being evaluated in early clinical studies. The primary focus of current research is on its pharmacokinetic, pharmacodynamic characteristics, and safety profile in healthy volunteers. As of 2025, clinical development has reached Phase 1 trials in both South Korea and the United States for cardiovascular indications, specifically essential hypertension[1][2][3][4][5][6]. The precise mechanism of action and molecular target have not been publicly disclosed.